These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 19596575)

  • 1. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
    Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
    El-Deeb IM; Park BS; Jung SJ; Yoo KH; Oh CH; Cho SJ; Han DK; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5622-6. PubMed ID: 19700314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity.
    El-Deeb IM; Lee SH
    Bioorg Med Chem; 2010 Jun; 18(11):3961-73. PubMed ID: 20472440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.
    Abdelazem AZ; Al-Sanea MM; Park BS; Park HM; Yoo KH; Sim T; Park JB; Lee SH; Lee SH
    Eur J Med Chem; 2015 Jan; 90():195-208. PubMed ID: 25461320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.
    Park BS; Al-Sanea MM; Abdelazem AZ; Park HM; Roh EJ; Park HM; Yoo KH; Sim T; Tae JS; Lee SH
    Bioorg Med Chem; 2014 Aug; 22(15):3871-8. PubMed ID: 24997577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of new pyrimidine-4-yl-ethanol derivatives as ROS1 kinase inhibitors.
    Abdelazem AZ; Lee SH
    J Enzyme Inhib Med Chem; 2015 Apr; 30(2):290-8. PubMed ID: 24939104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
    Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
    Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1.
    Wang Y; Zhang G; Hu G; Bu Y; Lei H; Zuo D; Han M; Zhai X; Gong P
    Eur J Med Chem; 2016 Nov; 123():80-89. PubMed ID: 27474925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of new anticancer pyrimidines with multiple-kinase inhibitory effect.
    El-Deeb IM; Lee SH
    Bioorg Med Chem; 2010 Jun; 18(11):3860-74. PubMed ID: 20471842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
    Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
    J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
    Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D
    J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
    Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.